Promising but Unpredictable Biotechs
Last week, I wrote about a couple of small biotechs on the upswing.
The upside trends in the sector were continuing Monday, following Bristol-Myers' (BMY) acquisition of Amylin Pharmaceuticals (AMLN), maker of diabetes treatments. The companies agreed on the $7 billion deal late Friday....451 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.